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Abstract
Background: Small bowel tumors are rare, accounting for only 3-6% of gastrointestinal neoplasms,
1-2% of these being malignant. They must be considered whenever a patient presents with
gastrointestinal bleeding, with normal upper gastrointestinal endoscopy and colonoscopy.
Case presentation: We report a case of jejunal adenocarcinoma presenting as a blood loss anemia
in a 65 year-old male, doing a brief review on the subject.
Conclusion: Our case intends to highlight the fact that small bowel tumours are rare and frequently
present to the Internist as non-specific clinical symptoms.
Background
Small bowel tumors are rare, accounting for only 3-6% of
gastrointestinal neoplasms, 1-2% of these being malignant
[1,2]. The diagnosis is usually made in an advanced stage
due to non-specific clinical symptoms [3]. In up to 5% of
gastrointestinal bleedings the source remains unidentified
after upper and lower endoscopic examination. In these
cases, one must consider lesions in the small bowel, being
vascular ectasias and tumors the most common causes.
Case presentation
A 65 year-old white male began symptoms of weakness for
medium efforts in March 2007. Two months later, during
one week, he had 2 episodes of dark feces, associated with
periumbilical pain, irradiating to the flancs and epigastric
area. He denied heart burn, pyrosis, regurgitation, post-
prandial fullness, nausea, vomiting, diarrhea and loss of
apetite. Blood tests revealed normocytic normochromic
anemia (hemoglobin = 11.1 g/dL), and upper gastro-
intestinal endoscopy was normal. During the next two
months there was aggravation of anemia (hemoglobin =
7.2 g/dL, mean globular volume = 67.6 fL) and progressive
asthenia, without evident blood loss or gastrointestinal
symptoms, coming then to the Emergency Room. The
patient had a past history of chronic hepatitis B, arterial
hypertension, gout, dislipidemia and had removed colo-
rectal polyps, with an unknown histologic diagnosis,
3 years before. He presented an alcohol consumption of
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and was medicated with losartan+hydrochlorothiazide,
allopurinol and simvastatin+ezetimibe. In the past 18
months the patient referred a weight loss of 15 kg.
Physical observation, apart from descoloration of skin and
mucous membranes, was unremarkable, revealing no
palpable adenomegaly (including absence of Virchow
node), no abdominal masses, and a normal digital rectal
examination. Blood tests confirmed a blood loss / iron-
deficiency anemia (serum iron = 4μg/dL, serum ferritin =
8.1 ng/dL, percent transferrin saturation = 1.06%, total
iron-binding capacity = 313 mg/dL), but were otherwise
normal. Chestx-Ray showed cardiomegaly and clear lungs.
The upper gastroduodenal endoscopy revealed no lesions.
Colonoscopy identified 3 polyps, with no signs of
bleeding, in the sigmoid, descendent colon and cecum,
corresponding to tubular adenomas with low-grade
dysplasia which did not seem to be responsible for the
clinical presentation. Since we were unable to proceed
with capsule endoscopy due to difficult availability in our
hospital, we decided to do an abdominal CT-scan, which
showed a diffuse upper jejunal thickening with local,
retrocural and peri-aortic adenomegaly, along with dis-
tension of D3 suggesting a suboclusive pattern (Fig. 1).
The day after the CT scan, the patient began with retching,
so programmed surgery was antecipated. Resection of
upper jejunum and regional lymph nodes, with jejuno-
duodenal anastomosis, was performed. The histologic
examination revealed an ulcerated, poorly diferentiated
adenocarcinoma - T4N2M0 (stage III) (Figs. 2 and 3).
Six months after surgery, follow-up CT scan revealed
evidence of local recurrence of the tumour, again with
lymph node involvement. The patient was proposed for
chemotherapy with six cycles of capecitabine. By the end
of the second cycle the patient started vomiting and
abdominal pain relieved by metochlopramide and diaze-
pam, allowing the third cycle. Due to recurrence of
symptoms and marked weight loss he then repeated the
CT scan, once more revealing diffuse upper jejunal
thickening with distension of D3, extensive lymph node
dissemination (abdomen and thorax), and a single hepatic
metastasis at segment IV. A paliative bypass was performed
with successful symptomatic relieve and the patient is still
alive 14 months after diagnosis.
Figure 1. Diagnostic CT scan view showing diffuse upper
jejunal thickening.
Figure 2. Neoplasic cells stained with AE1/AE3, a pan-keratin
marker (40x), showing its epithelial origin.
Figure 3. The infiltrative character of this tumour presented
here with invasionof the muscularis propria (Hematoxilin &
Eosin, 100X).
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The small bowel corresponds to 75% of the digestive tract
lenght and 90% of its mucosal surface area [4], but
surprisingly the frequency of neoplasms is lower than in
the stomach or the large bowel. This apparent “neoplastic
resistance” finds its eventual explanation in the low
bacterial content capable of transforming food compo-
nents into carcinogens, along with the large amount of
alcaline fluid secretion, the rapid transit time, and the high
concentration of the enzyme benzopyrene hydroxylase,
which reduce the mucosal contact with potencial carcino-
gens [5].
In1746, Hamburger madethefirst casereport of duodenal
carcinoma, and the first review of malignant small bowel
neoplasms was published, in 1876, by Leichtenstein.
In 2007, the American Cancer Society reported 5640
new cases of small bowel tumors, with 1090 estimated
deaths [6]. A population-based study of the incidence of
malignant small bowel tumors made in the United States,
between 1973 and 1990, revealed an incidence rate per
million people of 3.7 for adenocarcinoma and 3.8 for
carcinoid, the 2 most common histologic types [5].
Data from Germany suggests an annual incidence of small
bowel adenocarcinomas of 2.2-5.7 per million people
each year [7].
The mean age of diagnosis of small bowel tumors is 60
years of age, with a slight male preponderance [1,2].
Adenocarcinoma is the most common histologic type
(30-50%). The other epithelial origin variants, like
mucinous adenocarcinoma or the small cell, signet-ring
cell, squamous and adenosquamous, medullary or even
undifferenciated are much rarer. The carcinoids (25-30%)
follow the lead, and in a lesser extent are the lymphomas
and sarcomas (which include gastrointestinal stromal
tumors). The frequency of small bowel tumours is higher
in the duodenum (38-55.2%), and decreases distally, with
17.6-33.3% cases localized in jejunum and 13-23.8% in
the ileum [2,4,8]
Small and large bowel adenocarcinomas share similar
pathologic (development from adenomatous polyps),
genetic (mutations of oncogene ras and elevated levels of
p53), and epidemiologic features [9]. Familial adenoma-
tous polyposis, hereditary non-polyposis colorectal can-
cer, Crohn´s disease, celiac disease and diet (animal fat,
read-meat and smoked/salted food) are the strongest risk
factors [4].
The diagnosis is usually delayed in about 6 to 8 months
due to nonspecific clinical symptoms. Abdominal pain
(50-75%), nausea / vomiting (3372.5%), weight loss
(38-52.5%), intestinal obstruction (31.3-44%), and gas-
trointestinal bleeding (23-33%) are the most common
symptoms [1,2,10]. At thetime of thediagnosis tumors are
already in an advance stage [1,2]. In a review of 217
adenocarcinomas, made by Dabala et al [3], 39% of the
patients were in TNM stage III and 35% in stage IV by the
time of the diagnosis.
Capsule endoscopy has become the most sensible and
specific diagnostic method for small bowel disease [11]. It
has increased the diagnostic rate of small bowel tumors,
most of them detected in cases of obscure gastrointestinal
bleeding, with 50-60% of these being malignant. The
capsule has overcome the low sensitivity of barium studies
(30-50%), and the discomfort and complexity of push and
sonde enteroscopy. The upper gastrointestinal endoscopy
cannot pass beyond the Treitz ligament so, although it
identifies around 93% of duodenal tumors, its overall
sensitivity is only 31%. CT scan misses 43% of small
bowel tumors [1].
Surgical resection is the only hope of cure for patients with
small bowel adenocarcinoma. Pancreatoduodenectomy is
performed in tumors of the first and second portion of the
duodenum, while resection followed by anastomosis is
the option for tumors located elsewhere. In each case,
resection must include regional lymphadenectomy due to
the high prevalence of lymph node metastasis at the time
of presentation. Curative resection of small bowel tumors
is obtained in about 50% [1]. In a recent review, made by
Agrawal et al [10], curative resection for adenocarcinoma
was performed in 54.5% of cases, with a 3.6% post-
operative mortality rate. Despite curative surgery, the
disease will eventually recur in half of the patients with
lymph node, hepatic or lung metastasis.
Chemotherapy for small bowel tumors is still a matter of
debate. There are no randomised controlled trials to
evaluate the effectiveness of adjuvant chemotherapy for
adenocarcinoma of the small intestine, and so no optimal
chemotherapy regimen has yet been established. In 1984,
Jigyasu et al [12] reported a small benefit in 3 of 21
patients with metastatic disease, and Ouriel and Adams
[13] observed a small increment of survival in 6 patients
with metastatic and 6 with recurrent disease, both studies
based on the use of chemotherapy regimens containing
5-fluorouracil. In a study, by Crawley et al [14] in 1998,
3 of 8 patients with advanced diseased showed good
response to the same chemotherapy agent. Agents used in
colorectal carcinoma have also been used in small bowel
adenocarcinoma. Polyzos et al [15] used irinotecam in 3
patients with disease refractory to 5-fluorouracil, obtain-
ing minor responses and some improvement in symp-
toms. Some recent studies have failed to prove a clear
benefit of adjuvant chemotherapy [3].
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survival. It is technically difficult to localize the target field
due to the mobile nature of the small intestine mesentery.
The prognosis of small bowel tumors is poor, with most
series reporting a 5-year-survival of 15-35%. After curative
surgical resection this rate increases to 40-65% in most
studies. In 1999, Howe et al [8] presented a review of 4995
cases of adenocarcinoma, and defined patient age over 75,
duodenal localization, advanced stage and absence of
surgery treatment as negative prognosis factors. Adeno-
carcinoma seems to be the second histologic type with the
best suvival rate, as reported by Talamonti et al [2]. In this
review 37% of the patients with adenocarcinomas were
alive 5 years after the diagnosis with a median survival of
30 months, surpassed only by carcinoids (64%), and in
contrast to sarcomas (22%) and lymphomas (29%).
Median survival for incomplete resected adenocarcinomas
was 9 months, increasing to 40 months, with a 5-year
survival rate of 42%, for completely resected adenocarci-
nomas, which supports the positive prognostic value of
surgery.
Conclusion
Our case intends to highlight the fact that small bowel
tumours are rare and frequently present to the Internist as
non-specific clinical symptoms. Although capsule endo-
scopy has become the most sensible and specific
diagnostic method for small bowel disease, the use of
other diagnostic tools, like CT scan, are still a valid option
where capsule is not easily available. Despite surgery and
trial of chemotherapy the disease tends to recur conferring
a poor prognosis to this rare gastrointestinal tumor.
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